Atlas Trials

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

Clinical trial NCT05142592 · COMPLETED

Trial details

NCT number
NCT05142592
Sponsor
Nanjing Immunophage Biotech Co., Ltd
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Safety IssuesTolerabilityPharmacokinetics
Start date
2021-11-15
Primary completion
2026-02-08
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.